Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.

MLA

Hentzien, Maxime, et al. “Immune Response to the Recombinant Herpes Zoster Vaccine in People Living with HIV over 50 Years of Age Compared to Non-HIV Age-/Gender-Matched Controls (SHINGR’HIV): A Multicenter, International, Non-Randomized Clinical Trial Study Protocol.” BMC Infectious Diseases, vol. 24, no. 1, Mar. 2024, p. 329. EBSCOhost, https://doi.org/10.1186/s12879-024-09192-5.

APA

Hentzien, M., Bonnet, F., Bernasconi, E., Biver, E., Braun, D. L., Munting, A., Leuzinger, K., Leleux, O., Musardo, S., Prendki, V., Schmid, P., Staehelin, C., Stoeckle, M., Walti, C. S., Wittkop, L., Appay, V., Didierlaurent, A. M., & Calmy, A. (2024). Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocol. BMC Infectious Diseases, 24(1), 329. https://doi.org/10.1186/s12879-024-09192-5

Chicago

Hentzien, Maxime, Fabrice Bonnet, Enos Bernasconi, Emmanuel Biver, Dominique L Braun, Aline Munting, Karoline Leuzinger, et al. 2024. “Immune Response to the Recombinant Herpes Zoster Vaccine in People Living with HIV over 50 Years of Age Compared to Non-HIV Age-/Gender-Matched Controls (SHINGR’HIV): A Multicenter, International, Non-Randomized Clinical Trial Study Protocol.” BMC Infectious Diseases 24 (1): 329. doi:10.1186/s12879-024-09192-5.